Researchers randomized patients with advanced neuroendocrine tumors 2:1 to receive either cabozantinib or placebo.

Pharmaceutical ads are difficult to avoid in American television programming and a growing number of them promote a class of ...

Dr. Weickert will present Pacylex at the OBIO® Investment Summit and Early Technology Showcase February 5-7, 2025, at the Arcadian Court & Loft, Toronto Mr. Kamdar will present Pacylex at the PWMC ...

Sorafenib is an oral multikinase inhibitor that inhibits tumor growth and proliferation by interfering with several receptor tyrosine kinases involved in the pathogenesis and perpetuation of ...

DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight” report provides comprehensive insights about 80+ companies ...

Over the past two decades, the idea of targeting transcription factors to combat malignancies has turned into a clinical reality.

Hepatocellular carcinoma (HCC) is a common malignant tumor of which the occurrence and development, the tumorigenicity of HCC is involving in multistep and multifactor interactions. Interleukin-6 ...

to ErbB receptors activates a sequence of canonical intracellular pathways downstream from many receptor tyrosine kinases (RTKs), such as phosphatidylinositol-3-kinase (PI3K)/Akt/mammalian target of ...

Murine hematopoietic cells were transduced with ecotropic supernatants (Figure 1b), using conditions that led to efficient gene marking with low provirus copies (<3) per cell. 23 Polyclonal ...